g0d4ather / Shutterstock.com
4 January 2017Americas
Amgen secures patent win in Repatha case
Amgen secured victory yesterday as a US federal judge refused to throw out a ruling upholding the validity of two patents owned by the company.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
6 January 2017 Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
9 January 2017 Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.
Editor's picks
Editor's picks
Americas
6 January 2017 Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
9 January 2017 Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.
Americas
6 January 2017 Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
9 January 2017 Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.